, Volume 173, Issue 1–2, pp 227–228 | Cite as

Case report: successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine

  • Jaskaran SinghEmail author
  • Carlos A. ZarateJr
  • Andrew D. Krystal
Letter to the Editors


Bipolar affective disorder is a common, severe, chronic and often life-threatening illness (Goodwin and Jamison 1990). Increasingly, it is recognized that the depressive phase of the illness contributes to much of the morbidity and mortality associated with bipolar disorder (Simpson and Jamison 1999). While treatments for acute unipolar depression have been extensively researched, few studies have examined the efficacy of somatic treatments for the acute phase of bipolar depression (Keck et al. 2003), and treatment with antidepressants remains controversial (Ghaemi et al. 2003; Goodwin 2003). Lamotrigine is a putative inhibitor of glutamate release through inhibition of voltage-dependant Na+ and Ca2+ channels, and is effective in bipolar depression (Calabrese et al. 1999). The FDA has recently approved lamotrigine for relapse prevention in bipolar I disorder. Although generally well tolerated, the development of a rare but serious rash may necessitate lamotrigine...


Bipolar Disorder Amyotrophic Lateral Sclerosis Olanzapine Lamotrigine Venlafaxine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Calabrese JR, Bowden CL, Sachs GS et al. (1999) A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 60:79–88PubMedGoogle Scholar
  2. Calabrese JR, Sullivan JR, Bowden CL et al. (2002) Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry 63:1012–1019PubMedGoogle Scholar
  3. Ghaemi SN, Hsu DJ, Soldani F et al. (2003) Antidepressants in bipolar disorder: the case for caution. Bipolar Disord 5:421–433CrossRefPubMedGoogle Scholar
  4. Goodwin GM (2003) Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 17:149–173; discussion 147CrossRefPubMedGoogle Scholar
  5. Goodwin,FK, Jamison KR (1990) Manic-depressive Illness. Oxford University Press, New YorkGoogle Scholar
  6. Keck J, Paul E, Nelson EB, McElroy SL (2003) Advances in the pharmacologic treatment of bipolar depression. Biol Psychiatry 53:671–679CrossRefPubMedGoogle Scholar
  7. Prakriya M, Mennerick S (2000) Selective depression of low-release probability excitatory synapses by sodium channel blockers. Neuron 26:671–682PubMedGoogle Scholar
  8. Simpson SG, Jamison KR (1999) The risk of suicide in patients with bipolar disorders. J Clin Psychiatry 60 (Suppl 2):53–56; discussion 75–76, 113–116Google Scholar
  9. Zarate CA Jr, Payne JL, Quiroz JA, Sporn J, Denicoff KD, Luckenbaugh D, Charney DS, Manji HK (2004) An open-label trial of riluzole in treatment-resistant major depression. Am J Psychiatry 161:171–174CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Jaskaran Singh
    • 1
    Email author
  • Carlos A. ZarateJr
    • 1
  • Andrew D. Krystal
    • 2
  1. 1.Laboratory of Molecular PathophysiologyNational Institutes of Mental HealthBethesdaUSA
  2. 2.Duke University Medical CenterDurhamUSA

Personalised recommendations